$Efficacy of Humanized Anti-BCMA CAR T Cell Therapy in Relapsed/Refractory Multiple Myeloma Patients With and Without Extramedullary Disease$

Efficacy of Humanized Anti-BCMA CAR T Cell Therapy in Relapsed/Refractory Multiple Myeloma Patients With and Without Extramedullary Disease

In recent years, many new treatments for relapsed/refractory (R/R) multiple myeloma (MM) have improved patient prognosis, but the prognosis of patients with extramedullary MM is still particularly poor. Therefore, more efficacious therapies and novel strategies are urgently needed for these patients...

Full description

Bibliographic Details
Main Authors:	Haobin Deng, Meijing Liu, Ting Yuan, Huan Zhang, Rui Cui, Jingyi Li, Jijun Yuan, Xiaofang Wang, Yafei Wang, Qi Deng
Format:	Article
Language:	English
Published:	Frontiers Media S.A. 2021-08-01
Series:	Frontiers in Immunology
Subjects:	anti-B cell maturation antigen chimeric antigen receptor T multiple myeloma relapsed refractory extramedullary disease efficacy
Online Access:	https://www.frontiersin.org/articles/10.3389/fimmu.2021.720571/full

Similar Items

A novel two-step administration of XPO-1 inhibitor may enhance the effect of anti-BCMA CAR-T in relapsed/refractory extramedullary multiple myeloma
by: Di Wang, et al.
Published: (2023-11-01)

Impact of glucocorticoids on short-term and long-term outcomes in patients with relapsed/refractory multiple myeloma treated with CAR-T therapy
by: Xue Wang, et al.
Published: (2022-08-01)

Ciltacabtagene Autoleucel for the Treatment of Relapsed/Refractory Multiple Myeloma: Efficacy, Safety, and Place in Therapy
by: Goel U, et al.
Published: (2025-02-01)

Efficacy of Bendamustine, Pomalidomide, and Dexamethasone (BPD) Regimen in Relapsed/Refractory Extramedullary Myeloma: A Retrospective Single-Centre Study, Real-Life Experience
by: İbrahim Halil Açar, et al.
Published: (2023-08-01)

Targeting BCMA in multiple myeloma: designs, challenges, and future directions
by: Yi Hu, et al.
Published: (2025-02-01)

Idiopathic thrombocytopenic purpura treatment in a relapsed/refractory multiple myeloma patient after chimeric antigen receptor T cell therapy
by: Lei Qiu, et al.
Published: (2020-06-01)

Therapeutic effect of CAR-γδT cells targeting at BCMA in multiple myeloma
by: LI Yinghui, XU Yi, ZHANG Jianmin, CHEN Hui, HE Wei
Published: (2024-06-01)

A combination of pre-infusion serum ferritin, CRP and IL-6 predicts outcome in relapsed/refractory multiple myeloma patients treated with CAR-T cells
by: Yang Liu, et al.
Published: (2023-04-01)

Isolated Non-Secretory Extramedullary Relapse of Multiple Myeloma Responded Completely to Localized Radiotherapy
by: Danny Dawd, et al.
Published: (2024-03-01)

A novel generation 1928zT2 CAR T cells induce remission in extramedullary relapse of acute lymphoblastic leukemia
by: Jianyu Weng, et al.
Published: (2018-02-01)

A rare case of multiple myeloma with intracranial extramedullary relapse: One or more myeloma clones?
by: Uros Markovic, et al.
Published: (2019-09-01)

Efficacy and safety of chimeric antigen receptor T cells targeting BCMA and GPRC5D in relapsed or refractory multiple myeloma
by: Xu Yang, et al.
Published: (2024-12-01)

Comprehensive meta-analysis of anti-BCMA chimeric antigen receptor T-cell therapy in relapsed or refractory multiple myeloma
by: Lina Zhang, et al.
Published: (2021-01-01)

CAR-T cell therapy in relapsed or refractory multiple myeloma and access in Turkey
by: Goker Hakan, et al.
Published: (2024-08-01)

Anti-BCMA CAR-T cells for treatment of plasma cell dyscrasia: case report on POEMS syndrome and multiple myeloma
by: Jinhuan Xu, et al.
Published: (2018-10-01)

Case report: Plasma cell leukemia secondary to multiple myeloma successfully treated with anti-BCMA CAR-T cell therapy
by: Jingjing Deng, et al.
Published: (2022-09-01)

How I treat relapsed and/or refractory multiple myeloma
by: Hans C. Lee, et al.
Published: (2020-09-01)

Preclinical delayed toxicity studies of BCMA CAR T-cell injection in B-NDG mice with multiple myeloma
by: Jianmin Guo, et al.
Published: (2024-11-01)

Carfilzomib for relapsed and refractory multiple myeloma
by: Groen K, et al.
Published: (2019-04-01)

Prolonged hematological toxicity in patients receiving BCMA/CD19 CAR-T-cell therapy for relapsed or refractory multiple myeloma
by: Hujun Li, et al.
Published: (2022-10-01)

Efficacy and side effects of anti‐CD19 CAR T‐cell therapy in patients with relapsed/refractory gastrointestinal lymphoma
by: Yi Li Jiang, et al.
Published: (2024-02-01)

Four-year follow-up of LCAR-B38M in relapsed or refractory multiple myeloma: a phase 1, single-arm, open-label, multicenter study in China (LEGEND-2)
by: Wan-Hong Zhao, et al.
Published: (2022-07-01)

The CAR-HEMATOTOX score as a prognostic model of toxicity and response in patients receiving BCMA-directed CAR-T for relapsed/refractory multiple myeloma
by: Kai Rejeski, et al.
Published: (2023-07-01)

CAR NK92 Cells Targeting BCMA Can Effectively Kill Multiple Myeloma Cells Both In Vitro and In Vivo
by: Eunhee Park, et al.
Published: (2024-01-01)

Case report: sub-clinical extramedullary B-ALL in the setting of relapse following targeted therapy
by: Claire Johns, et al.
Published: (2024-09-01)

Incidence, clinical characteristics and prognosis of tumor lysis syndrome following B-cell maturation antigen-targeted chimeric antigen receptor-T cell therapy in relapsed/refractory multiple myeloma
by: Qiqi Zhang, et al.
Published: (2023-05-01)

BCMA/CD47-directed universal CAR-T cells exhibit excellent antitumor activity in multiple myeloma
by: Qizhong Lu, et al.
Published: (2024-05-01)

Correlation of Cytokine Release Syndrome With Prognosis After Chimeric Antigen Receptor T Cell Therapy: Analysis of 54 Patients With Relapsed or Refractory Multiple Myeloma
by: Xue Wang, et al.
Published: (2022-04-01)

Humanized CD19 CAR-T cells in relapsed/refractory B-ALL patients who relapsed after or failed murine CD19 CAR-T therapy
by: Lihong An, et al.
Published: (2022-04-01)

A systematic review on the epidemiology and treatment options of multiple Myeloma in Asia
by: Wee-Joo Chng, et al.
Published: (2024-11-01)

Recent updates on CAR T clinical trials for multiple myeloma
by: Quande Lin, et al.
Published: (2019-11-01)

Infections associated with CAR‐T cell therapy in patients with relapsed refractory multiple myeloma: Risks and prevention strategies
by: Jing An, et al.
Published: (2024-06-01)

Efficacy and Safety of Dual-targeted Chimeric Antigen Receptor-T Cell Therapy in Patients with Refractory-relapsed Multiple Myeloma: a Meta-analysis
by: YU Haibo, ZHANG Tianyu, LI Xin, ZHANG Jiajia, SHEN Man, ZHAN Xiaokai, TANG Ran, FAN Sibin, ZHAO Fengyi, HUANG Zhongxia
Published: (2024-03-01)

Extramedullary relapse of multiple myeloma defined as the highest risk group based on deregulated gene expression data
by: Sabina Sevcikova, et al.
Published: (2015-06-01)

A rare case of bifocal, extramedullary and hyposecretory relapse of multiple myeloma
by: Jiri Minarik, et al.
Published: (2021-08-01)

CD7-directed CAR T-cell therapy: a potential immunotherapy strategy for relapsed/refractory acute myeloid leukemia
by: Xuanqi Cao, et al.
Published: (2022-09-01)

Effectiveness and safety of anti-BCMA chimeric antigen receptor T-cell treatment in relapsed/refractory multiple myeloma: a comprehensive review and meta-analysis of prospective clinical trials
by: Dingyuan Hu, et al.
Published: (2023-06-01)

Daratumumab combined with dexamethasone and lenalidomide or bortezomib in relapsed/refractory multiple myeloma (RRMM) patients: Report from the multiple myeloma GIMEMA Lazio group
by: Francesca Fazio, et al.
Published: (2022-02-01)

BCMA CAR-T therapy combined with pomalidomide is a safe and effective treatment for relapsed/refractory multiple myeloma
by: Yuhan Yan, et al.
Published: (2024-11-01)

Beyond BCMA: the next wave of CAR T cell therapy in multiple myeloma
by: Kevin Miller, et al.
Published: (2024-05-01)